A recent study finds that the prevalence of post-COVID-19 condition was 8.4 percent among U.S. adults in 2023.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

A brief outpatient rehabilitation program with a cognitive and behavioral approach is effective for patients with post-COVID-19 condition.

HealthDay News — Substance use among adolescents has continued to hold steady at lowered levels for the fourth year in a row, according to the U.S. National Institutes of Health (NIH)-funded ...

Gestational hypertension, preeclampsia, and eclampsia are associated with an increased risk for neurological outcomes after giving birth.

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found when comparing healthy controls.

Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade,” the authors write. “The most notable decrease was in the South, which ...